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3-kg weight loss (mainly fat mass), attributed predominantly to glycosuria and resultant calorie loss. 16 Additionally, a small but significant reduction of 2 to 3 mm Hg in systolic blood pressure has been observed. The underlying mechanisms of the blood pressure effects may involve: fluid loss, reduced renin angiotensin system activity as a result of tubular glomerular feedback, 17, 18 improved vascular function, and alterations in hormonal signalling as extrarenal protective effects. [19] [20] [21] The main adverse events identified to date with this drug class include increased risk for genital mycotic and urinary tract infections. 22 From post-marketing data, safety communications have been issued for a potential increased risk of (euglycaemic) diabetic ketoacidosis (DKA) 23, 24 and a US Food and Drug Administration (FDA) warning regarding a risk of acute renal failure. 25 A numerical imbalance was observed in the incidence of transitional cell carcinoma of the bladder in phase II to III of the dapagliflozin development programme. 22 Dapagliflozin has been approved for use in type 2 diabetes by worldwide regulators, including in the United States, having met pre-marketing safety requirements.
In 2008, the FDA published guidance to the pharmaceutical industry regarding the establishment of cardiovascular (CV) safety of new GLAs. 26 The first CV safety trial completed with SGLT2 inhibitors was the EMPA-REG OUTCOME trial that assessed the CV safety of empagliflozin in 7020 patients with type 2 diabetes and prevalent atherosclerotic CVD. 27 The trial was the first CV outcome trial (CVOT) of a GLA that demonstrated not only the CV safety but also the CV superiority. Empagliflozin was shown to reduce the primary composite endpoint of CV death, myocardial infarction (MI) or stroke, as well as CV mortality, total mortality, hospitalization for heart failure (HF) and several renal outcomes. 27, 28 The subsequently published results of the Canagliflozin Cardiovascular Assessment Study (CANVAS) programme also demonstrated a reduction in the composite primary CV endpoint with canagliflozin. 29 There has not yet been a completed CVOT with dapagliflozin but its CV safety in populations with varying CV risk profiles was assessed in a dedicated meta-analysis 30 and as part of a larger meta-analysis that examined the CV safety of all SGLT2 inhibitors.
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The DECLARE-TIMI 58 trial is a randomized trial designed to establish the CV safety and potential CV benefit of dapagliflozin in a large and diverse population of patients with type 2 diabetes and either CV disease (CVD) or multiple risk factors (MRF) for CVD.
| STUDY DESIGN AND POPULATION
The DECLARE-TIMI 58 trial (NCT01730534) is a multicentre, multinational, double-blind, placebo-controlled, phase IIIb study, with primary safety and co-primary efficacy endpoints. The primary safety objective of the trial is to establish that dapagliflozin is non-inferior to placebo by demonstrating that the upper boundary of the 2-sided 95% confidence interval (CI) for the estimated risk ratio comparing the time to first event of the composite major adverse cardiovascular event (MACE) endpoint of CV death, non-fatal MI, or non-fatal ischaemic stroke observed with dapagliflozin vs placebo is <1.3, as mandated by the FDA guidance. 26 Other safety measurements that are collected throughout the trial include: serious adverse events and events of special interest. and Asia/Pacific, 12.7%, leading to a predominately white (79.6%) population ( Figure 1A ). Diabetes duration at baseline was heterogeneous, spanning from <5 to >20 years, with approximately half of the population having a disease duration of ≥10 years ( Figure 1B ).
Patients with CVD compared with those with MRF were more likely to be male (72.1% vs 56.1%), and had similar diabetes duration (12.0 vs 11.7 years) and mean HbA1c (8.33% vs 8.26%). Both subgroups had a high prevalence of CV risk factors, especially medically treated hypertension (87.7% and 90.6% in the CVD and MRF groups, respectively). Nearly 10% (n = 1698) of the overall trial population had HF at baseline and >6% had atrial fibrillation at baseline, both collected by the investigators using specific questions (Table 1) . Data regarding HF at baseline and during the trial that were retrospectively and prospectively collected included ejection fraction wherever available.
There was less use of metformin and sulphonylureas in the CVD group compared with the MRF group (74.6% vs 81.2% and 38.0% vs 43.2%, respectively). There was greater use of insulin in the CVD group compared with the MRF group (44.2% vs 36.4%; Figure 1C ).
There was a high level of use of anti-hypertensive medication in the trial, with a markedly higher use of β-blockers in the CVD group (66.6% vs 32.3%; Figure 1D ). There was higher use of anti-platelet and anti-coagulant agents in the CVD group (aspirin: 71.1% vs 39.1%;
clopidogrel: 24.7% vs 1.5%; warfarin: 6.1% vs 3.5%; and non-vitamin K antagonist oral anticoagulant: 2.1% vs 1.1% [ Figure 1E ]). Lastly, there was higher use of lipid-lowering agents, most noticeably statins, in the CVD group (82.2% vs 63.7%) ( Figure 1F ).
Previous MI, percutaneous coronary intervention and coronary artery bypass grafting were reported in 20.9%, 21.3% and 9.8% of the entire trial population, respectively, and in 51.4%, 52.4% and 24.1% of the CVD population, respectively ( Table 2 ). Previous ischaemic stroke was recorded in 6.5% and 15.9% of the entire study population and the CVD group (Table 2 ).
There were very small differences in baseline blood pressure (both systolic and diastolic), LDL and HDL cholesterol, triglycerides and eGFR between the MRF and CVD groups (Table 3) .
While creatinine clearance <60 mL/min (based on the 29 The DECLARE-TIMI 58 trial with its larger and broader population and the planned longer follow-up will distinguish this trial from previously published CVOTs with SGLT2 inhibitors.
In EMPA-REG OUTCOME and the CANVAS programme, the risks for hospitalization for HF were reduced by 35% (HR 0.65, 95%
CI 0.50-0.85) and 33% (HR 0.67, 95% CI 0.52-0.87), respectively.
27,29
The DECLARE-TIMI 58 with combined co-primary efficacy outcomes of MACE and the composite endpoint of CV death or hospitalization for HF will provide an important view on common and important cardiac outcomes in patients with type 2 diabetes.
The safety analysis of the DECLARE-TIMI 58 trial will provide data for dapagliflozin in relation to some of the questions raised after the publication of the EMPA-REG trial and the CANVAS programme. 27,29 Both amputation-related and DKA events are actively sought and collected in specifically designed forms, thereby providing event rates for dapagliflozin and placebo and also ensuring a thorough collection of all the data related to these events.
The underlying hypothesis of the DECLARE-TIMI 58 trial is that the improvement in multiple metabolic and haemodynamic charac- of the larger MRF population in DECLARE TIMI 58 increases the potential applicability of the trial results to a larger population of patients in a real-world setting; however, the trial was designed and powered to confirm the primary outcome in the entire study population.
The length of median follow-up in the EMPA-REG OUTCOME and CANVAS programme was 3.1 and 2.4 years, respectively. The longer follow-up of patients in the DECLARE-TIMI 58 trial (expected to be >4 years), will enable us to better detect not only the immediate effects of the drug, but also its longer-term effects that may be attributable to favourable effects on mediators of atherosclerotic CVD risk (eg, blood pressure, weight, lipid profile, progression of kidney disease, etc.).
In addition, the large sample size, as well as the follow-up time will enable evaluation of bladder cancer as follow-up to the numerical imbalance of bladder cancer observed in the dapagliflozin phase II and III development programme.
The rapid recruitment into the trial was made possible by the large number of countries and sites participating. This enrolment pattern minimizes the risk of a time-dependent cohort effect caused by changes in background therapy as may be seen in trials in which the recruitment phase took several years 38 or in the combination of different trials, as was done in the CANVAS programme.
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The DECLARE-TIMI 58 trial has a high proportion of patients taking statins, anti-platelet and/or anti-coagulant agents, β-blockers and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers. 39 This is in accordance with the FDA guidance that requires demonstrating CV safety and possible benefit of new GLAs in addition to best available guideline-directed therapy. 26 Not surprisingly, there are differences in the frequency of use of CV drugs between the CVD and the MRF subgroups; most noticeably, in the CVD group there is a higher rate of use of: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, β-blockers, diuretics, mineralocorticoid receptor antagonists, aspirin, clopidogrel, statins and ezetimibe, where these agents are more clearly indicated in treatment guidelines. 39 Given the large sample size of the study, it will be possible to examine subgroups based on concomitant medication usage, but one would not expect an interaction by treatment affecting the overall analyses.
There are also differences between CVD and MRF populations regarding the distribution of GLAs, mainly higher use of insulin and lower use of metformin, sulphonylureas and dipeptidyl peptidase-4 inhibitors in the CVD group. These differences might be attributed to differences in diabetes duration or renal function between the two subgroups. The difference in GLA use between the two groups may also lead to differences in the rate of hypoglycaemia and its consequences.
The baseline mean eGFR in the EMPA-REG OUTCOME and CANVAS programme were 74.1 and 76.5 mL/min/1.73 m 2 , respectively, while in the DECLARE-TIMI 58 trial it was 86.1 mL/min/1.73 m 2 . It is possible that the different exclusion criteria in DECLARE TIMI 58 (creatinine clearance <60 mL/min) could affect its potential to show similar clinical renal outcomes to those observed in the EMPA-REG OUTCOME trial, which had more permissive renal inclusion criteria. 28 Despite the fact that the DECLARE-TIMI 58 population has less severe renal dysfunction than the other two reported CVOTs of SGLT2 inhibitors, the larger number of patients, the prolonged follow-up and the prespecification of renal outcomes in the analysis of the DECLARE-TIMI 58 trial ensure that the trial is powered to assess renal outcomes with dapagliflozin.
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In conclusion, the DECLARE-TIMI 58 population is broad and includes large groups of patients with established CVD as well as with MRF for CVD. This diverse population will strengthen the external applicability of the trial results. The trial will also help to delineate the impact of prolonged treatment with dapagliflozin, an SGLT2
inhibitor, on patients with type 2 diabetes at high risk for CVD. The trial will broaden our knowledge regarding the CV and renal safety, as well as the potential benefit of dapagliflozin. The results will guide future therapeutic decision-making in patients with type 2 diabetes and increased CV risk. Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clini-
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